BR112019018368B1 - composição oftálmica aquosa - Google Patents

composição oftálmica aquosa Download PDF

Info

Publication number
BR112019018368B1
BR112019018368B1 BR112019018368-0A BR112019018368A BR112019018368B1 BR 112019018368 B1 BR112019018368 B1 BR 112019018368B1 BR 112019018368 A BR112019018368 A BR 112019018368A BR 112019018368 B1 BR112019018368 B1 BR 112019018368B1
Authority
BR
Brazil
Prior art keywords
viscosity
present
composition
aqueous
examples
Prior art date
Application number
BR112019018368-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112019018368A2 (pt
Inventor
Takeshi Yamamura
Ayaka YAMAMURO
Emi IZUKURA
Moto KIMURA
Tomohiro Otsuka
Original Assignee
Wakamoto Pharmaceutical Co.,Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wakamoto Pharmaceutical Co.,Ltd filed Critical Wakamoto Pharmaceutical Co.,Ltd
Publication of BR112019018368A2 publication Critical patent/BR112019018368A2/pt
Publication of BR112019018368B1 publication Critical patent/BR112019018368B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
BR112019018368-0A 2017-04-25 2018-04-25 composição oftálmica aquosa BR112019018368B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2017-086512 2017-04-25
JP2017086512 2017-04-25
JP2017-249891 2017-12-26
JP2017249891 2017-12-26
PCT/JP2018/016854 WO2018199180A1 (ja) 2017-04-25 2018-04-25 熱ゲル化人工涙液

Publications (2)

Publication Number Publication Date
BR112019018368A2 BR112019018368A2 (pt) 2020-04-07
BR112019018368B1 true BR112019018368B1 (pt) 2021-03-02

Family

ID=63919901

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019018368-0A BR112019018368B1 (pt) 2017-04-25 2018-04-25 composição oftálmica aquosa

Country Status (16)

Country Link
US (2) US10532026B2 (cg-RX-API-DMAC10.html)
EP (1) EP3593806B1 (cg-RX-API-DMAC10.html)
JP (2) JP6473274B1 (cg-RX-API-DMAC10.html)
KR (2) KR102083253B1 (cg-RX-API-DMAC10.html)
CN (2) CN110913867B (cg-RX-API-DMAC10.html)
AU (1) AU2018257301B2 (cg-RX-API-DMAC10.html)
BR (1) BR112019018368B1 (cg-RX-API-DMAC10.html)
CA (1) CA3025567C (cg-RX-API-DMAC10.html)
ES (1) ES2912289T3 (cg-RX-API-DMAC10.html)
MX (2) MX379302B (cg-RX-API-DMAC10.html)
MY (2) MY196565A (cg-RX-API-DMAC10.html)
PH (1) PH12019502335A1 (cg-RX-API-DMAC10.html)
RU (1) RU2710366C1 (cg-RX-API-DMAC10.html)
SG (1) SG11201909170QA (cg-RX-API-DMAC10.html)
TW (1) TWI733019B (cg-RX-API-DMAC10.html)
WO (1) WO2018199180A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202007977RA (en) * 2018-02-28 2020-09-29 Santen Pharmaceutical Co Ltd Ophthalmic composition comprising diquafosol and cationic polymer
TW202000196A (zh) * 2018-03-01 2020-01-01 日商石原產業股份有限公司 保存安定性優異之醫藥組成物
WO2020175525A1 (ja) * 2019-02-27 2020-09-03 参天製薬株式会社 ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2125060C (en) * 1993-07-02 1999-03-30 Henry P. Dabrowski Ophthalmic solution for artificial tears
JP3450805B2 (ja) * 2000-08-08 2003-09-29 わかもと製薬株式会社 水性医薬組成物
JP2003095924A (ja) * 2001-07-16 2003-04-03 Wakamoto Pharmaceut Co Ltd 熱ゲル化人工涙液
GB0210794D0 (en) * 2002-05-10 2002-06-19 Chart Heat Exchangers Ltd Heat exchangers
JP4263456B2 (ja) 2002-03-18 2009-05-13 わかもと製薬株式会社 ヒアルロン酸含有熱ゲル化製剤
JP4263418B2 (ja) * 2002-03-18 2009-05-13 わかもと製薬株式会社 熱ゲル化人工涙液
EP1681065A4 (en) 2003-10-31 2011-12-28 Wakamoto Pharma Co Ltd WATER-BASED COMPOSITION SUBJECTED TO REVERSIBLE THERMOREGULATION
JP5649261B2 (ja) * 2004-05-07 2015-01-07 ロート製薬株式会社 高粘度点眼剤
JP5661981B2 (ja) * 2004-11-26 2015-01-28 大正製薬株式会社 眼科用剤
CN101784287B (zh) * 2007-06-26 2013-04-24 若素制药株式会社 水性组合物

Also Published As

Publication number Publication date
MX2018014935A (es) 2019-04-09
KR102281853B1 (ko) 2021-07-23
WO2018199180A1 (ja) 2018-11-01
EP3593806A4 (en) 2020-03-25
CN113332233B (zh) 2022-02-25
EP3593806B1 (en) 2022-03-30
JPWO2018199180A1 (ja) 2019-06-27
MX379302B (es) 2025-03-11
BR112019018368A2 (pt) 2020-04-07
MY196323A (en) 2023-03-24
KR20190110624A (ko) 2019-09-30
TW201842900A (zh) 2018-12-16
ES2912289T3 (es) 2022-05-25
KR102083253B1 (ko) 2020-03-02
RU2710366C1 (ru) 2019-12-26
PH12019502335A1 (en) 2020-09-14
JP6473274B1 (ja) 2019-02-20
CN113332233A (zh) 2021-09-03
AU2018257301A1 (en) 2019-08-22
KR20200020999A (ko) 2020-02-26
JP6736705B2 (ja) 2020-08-05
CN110913867B (zh) 2021-06-11
US20180360746A1 (en) 2018-12-20
MY196565A (en) 2023-04-19
JP2019104740A (ja) 2019-06-27
CA3025567C (en) 2019-10-22
US20200121592A1 (en) 2020-04-23
AU2018257301B2 (en) 2019-10-31
CN110913867A (zh) 2020-03-24
US11096889B2 (en) 2021-08-24
SG11201909170QA (en) 2019-11-28
TWI733019B (zh) 2021-07-11
CA3025567A1 (en) 2018-11-01
EP3593806A1 (en) 2020-01-15
US10532026B2 (en) 2020-01-14

Similar Documents

Publication Publication Date Title
ES2486793T3 (es) Sistema polimérico de administración para una solución a base de prostaglandina no viscosa sin conservantes
CN107362157B (zh) 用于医学和兽医学的眼科药物组合物
KR102796051B1 (ko) 디쿠아포솔 및 양이온성 폴리머를 함유하는 안과용 조성물
BR112014008314B1 (pt) Composição oftálmica e seu uso
BRPI0720434A2 (pt) Gel útil para liberação de fármacos oftálmicos
RU2700927C2 (ru) Офтальмологическая композиция, содержащая циклоспорин и трегалозу
BR112015018414B1 (pt) Lágrimas artificiais compreendendo hialuronato de sódio e carboximetilcelulose
JP7787129B2 (ja) 眼科組成物
US11096889B2 (en) Thermo-responsive gelling artificial lacrima
JP5649261B2 (ja) 高粘度点眼剤
JP2022164840A (ja) 眼科組成物
JP2014167034A (ja) 高粘度点眼剤
HK40017178A (en) Thermogelling artificial tears
HK40017178B (en) Thermogelling artificial tears
ES2992106T3 (es) Composición oftálmica y su uso en el tratamiento de enfermedades oculares
WO2023048174A1 (ja) 角膜疾患治療剤
PT1927353E (pt) Medicamento para doenças corneais
BR112019021917A2 (pt) Composições de iodo
BR112020018377A2 (pt) Métodos de uso e composições farmacêuticas de um inibidor de syk seletivo
BR112020014265A2 (pt) Composições oftálmicas de uma vez ao dia de compostos de benzimidazol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/04/2018, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 7A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2824 DE 18-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.